Abstract

To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn’t need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019, of 225 had prebiopsy negative bpMRI (defined as Prostate Imaging Reporting and Data System (PI-RADS 2.1) score less than 3). The detection efficiency of clinically significant prostate cancer (CSPCa) was assessed according to age, digital rectal examination (DRE), prostate volume (PV) on bpMRI, prostate-specific antigen (PSA) and PSA density (PSAD). The definition of CSPCa for Gleason score > 6. Univariate and multivariable logistic regression analysis were used to identify predictive factors of absent CSPCa on PBs. Moreover, absent CSPCa contained clinically insignificant prostate cancer (CIPCa) and benign result. The detection rates of present prostate cancer (PCa) and CSPCa were 27.11% and 16.44%, respectively. Patients who were diagnosed as CSPCa had an older age (P < 0.001), suspicious DRE (P < 0.001), a smaller PV (P < 0.001), higher PSA value (P = 0.008) and higher PSAD (P < 0.001) compared to the CIPCa group and benign result group. PSAD < 0.15 ng/ml/cm3 (P = 0.004) and suspicious DRE (P < 0.001) were independent predictors of absent CSPCa on BPs. The negative forecast value of bpMRI for BP detection of CSPCa increased with decreasing PSAD, mainly in patients with naive PB (P < 0.001) but not in prior negative PB patients. 25.33% of the men had the combination of negative bpMRI, PSAD < 0.15 ng/ml/cm3 and PB naive, and none had CSPCa on repeat PBs. The incidence of PB was determined, CSPCa was 1.59%, 0% and 16.67% in patients with negative bpMRI and PSAD < 0.15 ng/ml/cm3, patients with negative bpMRI, PSAD < 0.15 ng/ml/cm3 and biopsy naive and patients with negative bpMRI, PSAD < 0.15 ng/ml/cm3 and prior negative PB, separately. We found that a part of patients with negative bpMRI, a younger age, no suspicious DRE and PSAD < 0.15 ng/ml/cm3 may securely avoid PBs. Conversely PB should be considered in patients regardless of negative bpMRI, especially who with a greater age, obviously suspicious DRE, significantly increased PSA value, a significantly small PV on MRI and PSAD > 0.15 ng/ml/cm3.

Highlights

  • Multi-parametric magnetic resonance imaging has marvelously sensitive power in detecting clinically significant prostate cancer (CSPCa)[1]

  • Contrast among CSPCa, clinically insignificant prostate cancers (CIPCa) and benign groups showed that prostate-specific antigen (PSA), age, prostate volume (PV), PSA density (PSAD) and suspicious digital rectal examination (DRE) were statistically different among these groups (P = 0.008, remaining P < 0.001, Table 1, Fig. 2)

  • Comparing 37 patients with CSPCa to 188 with absent CSPCa, univariate analysis showed that a younger age (P = 0.001), lower PSA value (P = 0.003), greater prostate volume (PV, P < 0.001), lower PSAD (P = 0.011), especially PSAD < 0.15 ng/ml/cm[3] (P = 0.005) and suspicious DRE (P < 0.001) were predictors of detection of absent CSPCa in patients with negative MRI

Read more

Summary

Introduction

Multi-parametric magnetic resonance imaging (mpMRI) has marvelously sensitive power in detecting clinically significant prostate cancer (CSPCa)[1]. BpMRI has been displayed to have a diagnostic accuracy and PCa detection rate that are equivalent to those of mpMRI. There are still some debates about the interpretation of negative MRI It is still controversial whether prostate biopsies (PBs) are necessary for patients without suspected index lesions on bpMRI. In this case, because there is no targeted. We analyzed the retrospective data of a group of patients with prebiopsy negative MRI in order to determine the factors that influence the detection rate of PCa or CSPCa, with which we can establish a low risk of significant disease in patients with negative MRI. Biopsy can be avoided in this group and further clinical decisions for this population can be provided

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.